Skip to main content
Top
Published in: BMC Nephrology 1/2012

Open Access 01-12-2012 | Research article

Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion

Authors: Deborah Stuart, Sara Rees, Stephanie K Woodward, Robert Koesters, Kevin A Strait, Donald E Kohan

Published in: BMC Nephrology | Issue 1/2012

Login to get access

Abstract

Background

Endothelin, via endothelin A receptors (ETA), exerts multiple pathologic effects that contribute to disease pathogenesis throughout the body. ETA antagonists ameliorate many experimental diseases and have been extensively utilized in clinical trials. The utility of ETA blockers has been greatly limited, however, by fluid retention, sometimes leading to heart failure or death. To begin to examine this issue, the effect of genetic disruption of ETA in the nephron on blood pressure and salt handling was determined.

Methods

Mice were generated with doxycycline-inducible nephron-specific ETA deletion using Pax8-rtTA and LC-1 transgenes on the background of homozygous loxP-flanked ETA alleles. Arterial pressure, Na metabolism and measures of body fluid volume status (hematocrit and impedance plethysmography) were assessed.

Results

Absence of nephron ETA did not alter arterial pressure whether mice were ingesting a normal or high Na diet. Nephron ETA disruption did not detectably affect 24 hr Na excretion or urine volume regardless of Na intake. However, mice with nephron ETA knockout that were fed a high Na diet had mild fluid retention as evidenced by an increase in body weight and a fall in hematocrit.

Conclusions

Genetic deletion of nephron ETA causes very modest fluid retention that does not alter arterial pressure. Nephron ETA, under normal conditions, likely do not play a major role in regulation of Na excretion or systemic hemodynamics.
Appendix
Available only for authorised users
Literature
1.
go back to reference Battistini B, Berthiaume N, Kelland N, Webb D, Kohan D: Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. Exp Biol Med. 2006, 231: 653-695. Battistini B, Berthiaume N, Kelland N, Webb D, Kohan D: Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. Exp Biol Med. 2006, 231: 653-695.
2.
go back to reference Barton M, Yanagisawa M: Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008, 86: 485-498. 10.1139/Y08-059.CrossRefPubMed Barton M, Yanagisawa M: Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008, 86: 485-498. 10.1139/Y08-059.CrossRefPubMed
3.
go back to reference Barton M, Kohan DE: Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol. 2011, 172: 255-260.CrossRefPubMed Barton M, Kohan DE: Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol. 2011, 172: 255-260.CrossRefPubMed
4.
go back to reference Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010, 21: 527-535. 10.1681/ASN.2009060593.CrossRefPubMedPubMedCentral Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010, 21: 527-535. 10.1681/ASN.2009060593.CrossRefPubMedPubMedCentral
5.
go back to reference Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008, 113: 2478-2487. 10.1002/cncr.23864.CrossRefPubMedPubMedCentral Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008, 113: 2478-2487. 10.1002/cncr.23864.CrossRefPubMedPubMedCentral
6.
go back to reference Kohan DE, Rossi NF, Inscho EW, Pollock DM: Regulation of blood pressure and salt homeostasis by endothelin. Physiological Rev. 2011, 91: 1-77. 10.1152/physrev.00060.2009.CrossRef Kohan DE, Rossi NF, Inscho EW, Pollock DM: Regulation of blood pressure and salt homeostasis by endothelin. Physiological Rev. 2011, 91: 1-77. 10.1152/physrev.00060.2009.CrossRef
7.
go back to reference Ge Y, Stricklett PK, Hughes AK, Yanagisawa M, Kohan DE: Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol. 2005, 289 (4): F692-F698. 10.1152/ajprenal.00100.2005. Ge Y, Stricklett PK, Hughes AK, Yanagisawa M, Kohan DE: Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol. 2005, 289 (4): F692-F698. 10.1152/ajprenal.00100.2005.
8.
go back to reference Traykova-Brauch M, Schönig K, Greiner O, Miloud T, Jauch A, Bode M, Felsher DW, Glick AB, Kwiatkowski DJ, Bujard H, Horst J, von Knebel Doeberitz M, Niggli FK, Kriz W, Gröne HJ, Koesters R: An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nature Med. 2008, 14: 979-984. 10.1038/nm.1865.CrossRefPubMedPubMedCentral Traykova-Brauch M, Schönig K, Greiner O, Miloud T, Jauch A, Bode M, Felsher DW, Glick AB, Kwiatkowski DJ, Bujard H, Horst J, von Knebel Doeberitz M, Niggli FK, Kriz W, Gröne HJ, Koesters R: An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nature Med. 2008, 14: 979-984. 10.1038/nm.1865.CrossRefPubMedPubMedCentral
9.
go back to reference Chapman ME, Hu L, Plato CF, Kohan DE: Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. Am J Physiol. 2010, 299: F280-F283. 10.1152/ajprenal.00113.2010. Chapman ME, Hu L, Plato CF, Kohan DE: Bioimpedance spectroscopy for the estimation of body fluid volumes in mice. Am J Physiol. 2010, 299: F280-F283. 10.1152/ajprenal.00113.2010.
10.
go back to reference Bugaj V, Pochynyuk O, Mironova E, Vandewalle A, Medina JL, Stockand JD: Regulation of the epithelial Na + channel by endothelin-1 in rat collecting duct. Am J Physiol. 2008, 295: F1063-F1070. 10.1152/ajprenal.90321.2008. Bugaj V, Pochynyuk O, Mironova E, Vandewalle A, Medina JL, Stockand JD: Regulation of the epithelial Na + channel by endothelin-1 in rat collecting duct. Am J Physiol. 2008, 295: F1063-F1070. 10.1152/ajprenal.90321.2008.
11.
go back to reference Bugaj V, Mironova E, Kohan DE, Stockand JD: Collecting duct-specific endothelin B receptor knockout increases ENaC activity. Am J Physiol. 2012, 302: C188-C194. 10.1152/ajpcell.00301.2011.CrossRef Bugaj V, Mironova E, Kohan DE, Stockand JD: Collecting duct-specific endothelin B receptor knockout increases ENaC activity. Am J Physiol. 2012, 302: C188-C194. 10.1152/ajpcell.00301.2011.CrossRef
12.
go back to reference Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE: Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol. 2006, 291: F1274-F1280. 10.1152/ajprenal.00190.2006. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE: Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol. 2006, 291: F1274-F1280. 10.1152/ajprenal.00190.2006.
13.
go back to reference Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, Kohan DE: Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol. 2008, 295: F1635-F1640. 10.1152/ajprenal.90279.2008. Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, Kohan DE: Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol. 2008, 295: F1635-F1640. 10.1152/ajprenal.90279.2008.
14.
go back to reference Nakano D, Pollock DM: Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension. 2009, 53: 324-330.CrossRefPubMed Nakano D, Pollock DM: Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension. 2009, 53: 324-330.CrossRefPubMed
15.
go back to reference Evans NJ, Walker JW: Sustained Ca2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Can J Physiol Pharmacol. 2008, 86: 526-535. 10.1139/Y08-050.CrossRefPubMed Evans NJ, Walker JW: Sustained Ca2+ signaling and delayed internalization associated with endothelin receptor heterodimers linked through a PDZ finger. Can J Physiol Pharmacol. 2008, 86: 526-535. 10.1139/Y08-050.CrossRefPubMed
16.
go back to reference Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, Oksche A: Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem. 2004, 279: 27679-27687. 10.1074/jbc.M403601200.CrossRefPubMed Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, Oksche A: Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem. 2004, 279: 27679-27687. 10.1074/jbc.M403601200.CrossRefPubMed
17.
go back to reference Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011, 22: 763-772. 10.1681/ASN.2010080869.CrossRefPubMedPubMedCentral Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL: Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011, 22: 763-772. 10.1681/ASN.2010080869.CrossRefPubMedPubMedCentral
18.
go back to reference Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M: Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010, 56: 824-830. 10.1161/HYPERTENSIONAHA.110.156976.CrossRefPubMed Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M: Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010, 56: 824-830. 10.1161/HYPERTENSIONAHA.110.156976.CrossRefPubMed
Metadata
Title
Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion
Authors
Deborah Stuart
Sara Rees
Stephanie K Woodward
Robert Koesters
Kevin A Strait
Donald E Kohan
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2012
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-13-166

Other articles of this Issue 1/2012

BMC Nephrology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine